Cristina Galindo García, Claudia Moreno Pimentel, Reyes Serrano Giménez, Claudia Palomar Ávila, Manuel Castro Fernández, María José Fobelo Lozano
{"title":"Eosinophilic colitis with favorable response to vedolizumab.","authors":"Cristina Galindo García, Claudia Moreno Pimentel, Reyes Serrano Giménez, Claudia Palomar Ávila, Manuel Castro Fernández, María José Fobelo Lozano","doi":"10.17235/reed.2024.10660/2024","DOIUrl":null,"url":null,"abstract":"<p><p>Eosinophilic gastroenteritis is a rare, chronic inflammatory disease with eosinophil infiltration in the digestive tract. Treatment typically involves corticosteroids, but new therapies, including vedolizumab, are under evaluation. Vedolizumab inhibits lymphocyte migration to intestinal tissue, impacting eosinophil activity. We report a 34-year-old male with eosinophilic colitis, dependent on corticosteroids, who showed clinical improvement with vedolizumab. Despite a mild flare-up, intensifying vedolizumab resulted in prolonged stability and reduced steroid use over seventeen months. Although corticosteroids are the primary treatment, vedolizumab shows promise in some cases, warranting further investigation to confirm its effectiveness.</p>","PeriodicalId":21342,"journal":{"name":"Revista Espanola De Enfermedades Digestivas","volume":null,"pages":null},"PeriodicalIF":2.7000,"publicationDate":"2024-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista Espanola De Enfermedades Digestivas","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.17235/reed.2024.10660/2024","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Eosinophilic gastroenteritis is a rare, chronic inflammatory disease with eosinophil infiltration in the digestive tract. Treatment typically involves corticosteroids, but new therapies, including vedolizumab, are under evaluation. Vedolizumab inhibits lymphocyte migration to intestinal tissue, impacting eosinophil activity. We report a 34-year-old male with eosinophilic colitis, dependent on corticosteroids, who showed clinical improvement with vedolizumab. Despite a mild flare-up, intensifying vedolizumab resulted in prolonged stability and reduced steroid use over seventeen months. Although corticosteroids are the primary treatment, vedolizumab shows promise in some cases, warranting further investigation to confirm its effectiveness.
期刊介绍:
La Revista Española de Enfermedades Digestivas, Órgano Oficial de la Sociedad Española de Patología Digestiva (SEPD), Sociedad Española de Endoscopia Digestiva (SEED) y Asociación Española de Ecografía Digestiva (AEED), publica artículos originales, editoriales, revisiones, casos clínicos, cartas al director, imágenes en patología digestiva, y otros artículos especiales sobre todos los aspectos relativos a las enfermedades digestivas.